Dbv Technologies S A Stock Price, News & Analysis

DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company specializing in food allergies and immunologic treatments, has announced the filing of its 2025 Half-Year Report with the French market authority (AMF) for the period ending June 30, 2025.

The report is available in French on the company's website under the Investors/Financial Information section, on the AMF website, and can be requested directly from DBV Technologies via mail or email.

DBV Technologies (NASDAQ:DBVT) reported its Q2 and H1 2025 financial results, highlighting a challenging period with increased operating expenses and net losses. The company's operating expenses rose to $69.9 million for H1 2025, up from $65.0 million in H1 2024, primarily due to the COMFORT Toddlers safety study launch.

Net loss increased to $69.0 million in H1 2025 from $60.5 million in H1 2024, with loss per share at $(0.58). Cash position strengthened to $103.2 million as of June 30, 2025, boosted by a March financing deal of up to $306.9 million, including $125.5 million received in April. The company expects current cash to fund operations into Q2 2026, though substantial going concern doubts remain.

DBV Technologies (NASDAQ: DBVT) has released its half-year report regarding its liquidity contract with ODDO BHF. As of June 30, 2025, the liquidity account held 210,069 DBV Technologies shares and €171,301.08 in cash.

During H1 2025, the company executed 2,204 buy transactions and 2,398 sales transactions, with trading volumes of 1.16 million shares (€1.49M) purchased and 1.21 million shares (€1.56M) sold. This represents the activity since the contract's implementation on July 1, 2018, when the account started with 41,159 shares and €432,367.25.

DBV Technologies (NASDAQ: DBVT), a clinical-stage biopharmaceutical company, has appointed James Briggs as its new Chief Human Resources Officer, replacing Caroline Daniere. This strategic appointment comes as DBV prepares for its transition from a development-stage biotech to a potential commercial organization.

Briggs, who will report to CEO Daniel Tassé and join the Executive Committee, brings significant experience as a former Partner at East Bay Human Capital and CEO of MNG Health. He previously served as CHRO at several organizations including Ciox Health and Ikaria Inc. Briggs holds a Master's in Human Relations, is SPHR certified, and has a Six Sigma Green Belt certification.

DBV Technologies (NASDAQ:DBVT) has announced the screening of its first subject in the COMFORT Toddlers supplemental safety study for their Viaskin® Peanut patch 250 μg, targeting peanut-allergic children ages 1-3 years old.

The Phase 3 double-blind, placebo-controlled study will enroll approximately 480 subjects across 80-90 study centers in the U.S., Canada, Australia, UK, and Europe. The study includes a 6-month initial phase followed by an optional 18-month open-label treatment phase. The first screening took place at the Respiratory Medicine Research Institute of Michigan, with additional sites in Minnesota and Ontario now activated.

The data from this study will support a Biologics License Application (BLA) submission anticipated in 2H 2026 under the Accelerated Approval Pathway, complementing the previously completed Phase 3 EPITOPE study data.

DBV Technologies (DBVT) announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 13-16, 2025, in Glasgow, UK. The company will present two significant posters and host a symposium focused on their VIASKIN patch platform. Key presentations include data showing reduced reactions from accidental peanut consumption in Year 2 of the EPITOPE trial extension, and results from the APTITUDE Phase 2 study evaluating a diagnostic patch for non-IgE mediated cow's milk allergy in infants. The symposium "Peanut Allergy: Recent Research Highlights" will be co-chaired by prominent allergy experts and will feature discussions on patient-allergist relationships and new clinical data on epicutaneous immunotherapy for peanut allergy.

DBV Technologies (DBVT) held its 2025 Combined General Meeting, where shareholders approved all resolutions proposed by the Board of Directors. The meeting was presided over by Michel de Rosen, Chairman of the Company. The voting results and resolutions have been made available on the company's website in the Investors/Annual General Meetings section.

DBV Technologies (DBVT) has reported its monthly voting rights and share count as of May 30, 2025. The company disclosed a total of 136,973,697 shares outstanding, with gross voting rights matching this figure at 136,973,697. The net total of voting rights, which excludes shares without voting rights, stands at 136,738,528. This disclosure is made in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for companies listed on NYSE Euronext Paris.

DBV Technologies (DBVT) has filed an addendum to its 2024 Universal Registration Document with the French market authority (AMF). The addendum specifically updates the Board of Directors' Corporate Governance Report to include information about exceptional compensation granted to the Chief Executive Officer, as approved by the Board on April 30, 2025. This compensation payment requires shareholder approval at the upcoming Annual Combined General Meeting scheduled for June 11, 2025. Both the Universal Registration Document and addendum are accessible on DBV Technologies' website and the AMF website, with physical copies available at the company's headquarters in Châtillon, France.